china renaissance

Top private equity investors throw more weight behind the Chinese accounting software provider as it looks to expand its base into Japan and beyond.

Alibaba’s successful HK listing, combined with mounting pressure from PE investors, is forcing Chinese companies to consider listing in 2020 despite the woeful stock market performance of many who floated in 2019.

Biotech investment is the new gold rush in China. But firms still struggle to find steady investment from private equity players and industry heavyweights.

Chinese investors have been flying to India over the past few months to check out VC and PE investment opportunities. Can China follow in the footsteps of the Americans and the Japanese?

Lilly Asia Ventures, Oceanpine Capital, Matrix Partners China are betting on Ansun BioPharma to kill the virus on your respiratory tract.

As an investor and underwriter for companies listing on Shanghai's Nasdaq-style tech board, China Renaissance's chief executive Bao Fan urges China to allow for large-scale class-action lawsuits to boost investor confidence.

Investors have targeted the top private equity and venture capital firms as they hope to catch the next unicorn.

Chinese industrial products supplier introduces the tech giant as a new investor as it continues its transformation from old-economy company into a fully fledged online distributor.

Chief executive of the Chinese industrial robot maker tells FinanceAsia the firm is learning from the failure of its US peer as it raises $15 million for expansion.